Medications

PreclinicalSmall molecule

YYale University

Medications is one of 45 small molecule programs targeting Psychosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsychosisActive, not recruiting

Quality of LifeNot yet recruiting

Dental ImplantUnknown status

PsychosisPreclinical

Active, not recruiting

Quality of LifePreclinical

Not yet recruiting

Dental ImplantPreclinical

Unknown status

Competition

Competitive Landscape

40 competitors in Psychosis

#DrugCompanyPhaseTrials

Geodon

Pfizer

Approved

9 2

Abilify

Otsuka

Approved

18 3

Cysteine Hydrochloride

Novartis

Approved

2 4

Risperdal

WWim Janssens

Approved

11 5

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

8 6

Vraylar

Zyprexa

4 8

Niacor

AbbVie

Approved

—9

Barhemsys

Tibotec Pharmaceuticals, Ireland

Approved

3 10

Invega

WWim Janssens

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Depression1 trial

Prevention of Recurrence in Depression With Drugs and CT

Completed·VVanderbilt University·Phase 4·NCT00057577·452 enrolled

Quality of Life1 trial

Benson Relaxation Technique Effectiveness on Pain and Quality of Life Post Reconstructive Mammoplasty

Not yet recruiting·—·N/A·NCT07032883·68 enrolled

Dental Implant1 trial

Validation of the Jawbone Anatomy Classification in Endosseous Dental Implant Treatment

Unknown status·LLithuanian University of Health Sciences·N/A·NCT02054676·80 enrolled

Bone Regeneration1 trial

Guided Bone Regeneration Around Immediate Implants

Completed·UUniversity of Michigan·Phase 4·NCT01628367·32 enrolled

Psychosis1 trial

Specialized Treatment Early in Psychosis (STEP)

Completed·YYale University·N/A·NCT00309452·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Medications. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Medications compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Medications. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYale University

Medications

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Depression1 trial

Quality of Life1 trial

Dental Implant1 trial

Bone Regeneration1 trial

Psychosis1 trial

References

Drug Info

Quick Facts

Related News